Email this article 
Brachytherapy for prostate cancer: Comparative characteristics of procedures
- Authors: Kanaev S.V.1,2, Novikov S.N.1,2, Novikov R.V.3,2, Nosov A.K.3,2, Petrov S.B.3,2, Reva S.A.3,2
-
Affiliations:
- Department of Radiotherapy and Radionuclide Diagnosis N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia
- 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, Russia
- Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia
- Issue: Vol 11, No 2 (2015)
- Pages: 69-76
- Section: PROSTATE CANCER
- Published: 30.06.2015
- URL: https://oncourology.abvpress.ru/oncur/article/view/456
- DOI: https://doi.org/10.17650/1726-9776-2015-11-2-69-76
- ID: 456
Cite item
Full Text
Abstract
The introduction of interstitial radiation sources is the «youngest» of the radical method of treatment of patients with prostate cancer (PC). The high level of efficiency comparable to prostatectomy at a significantly lower rate of complications causes rapid growth of clinical use of brachytherapy (BT). Depending on the radiation source and the mode of administration into the prostate gland are two types BT – high-dose rate (temporary) (HDR-BT) and low-dose rate (permanent) (LDR-BT) brachytherapy. At the heart of these two methods are based on a single principle of direct effect of the quantum gamma radiation on the area of interest. However, the differences between the characteristics of isotopes used and technical aspects of the techniques cause the difference in performance and complication rates for expression HDR-BT and LDR-BT.
About the authors
S. V. Kanaev
Department of Radiotherapy and Radionuclide Diagnosis N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaRussian Federation
S. N. Novikov
Department of Radiotherapy and Radionuclide Diagnosis N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaRussian Federation
R. V. Novikov
Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, Russia
Author for correspondence.
Email: novikov-spb@mail.ru
Russian Federation
A. K. Nosov
Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaRussian Federation
S. B. Petrov
Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaRussian Federation
S. A. Reva
Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russia; 68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaRussian Federation
References
Supplementary files
